滚动资讯
CellRational design of G<sub>i</sub>-biased CB1 agonist with reduced side effectsCellThe spatiotemporal dynamics of postnatal vascularization in the mouse brainCellElectromagnetic field-inducible <em>in vivo</em> gene switch for remote spatiotemporal control of gene expressionFierceBiotechBain-backed Beeline Medicines buzzes out of stealth with $300M and 5 programs from BMSFierceBiotechTerremoto takes $108M series C to fuel clinical trials of AKT1 inhibitorsEndpoints NewsTerremoto raises $108M to make an 'earthquake' in small molecule spaceEndpoints NewsBeeline Medicines emerges as Bristol Myers' partner for shelved immunology drugsAgilentSumitomo Mitsui Trust Group Inc. Trims Stock Holdings in Agilent Technologies, Inc. $A - MarketBeatLonza NewsLonza AG Opens a New Bioprocessing Laboratory in Singapore - ChemAnalystFierceBiotechFDA official confirms plausible mechanism principles not exclusive to bespoke gene therapiesAgilentAssetmark Inc. Acquires 12,984 Shares of Agilent Technologies, Inc. $A - MarketBeatAgilentAgilent Technologies (A) Valuation Check After CRISPR Patent Loss And BioTek Cytation 9 Launch - simplywall.st
Cell 2026年4月15日

Rational design of G<sub>i</sub>-biased CB1 agonist with reduced side effects

Rational design of G i -biased CB1 agonist with reduced side effects

原文
暂时没有全文，请查看原始来源。

目录

1122 全部